koryu

NTLA long crispr/cas9

做多
koryu 已更新   
NASDAQ:NTLA   Intellia Therapeutics, Inc.
6
buying NTLA as long term investment in crispr/cas9 technology.
交易开始
评论:
bottom here would paint this channel
评论:
CRISPR stocks soar after chinese scientists start to crispr a human for the first time
评论:
added to position in this last dip, inv h+s, crispr hot!!
评论:
dump it -> go edit
交易手动结束

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。